{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:20:43Z","timestamp":1787311243566,"version":"build-2736575974"},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2017,6,5]],"date-time":"2017-06-05T00:00:00Z","timestamp":1496620800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Grant-in-Aid for Research on Advanced Chronic Kidney Disease, Practical Research Project for Renal Diseases from Japan Agency for Medical Research and development, AMED"},{"name":"Japan Dialysis Outcome Research","award":["2006-013"],"award-info":[{"award-number":["2006-013"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0178971","type":"journal-article","created":{"date-parts":[[2017,6,5]],"date-time":"2017-06-05T13:44:57Z","timestamp":1496670297000},"page":"e0178971","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":60,"title":["Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease"],"prefix":"10.1371","volume":"12","author":[{"given":"Marina","family":"Kohara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6893-7188","authenticated-orcid":true,"given":"Takahiro","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Shiizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsu","family":"Akimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumiko","family":"Honma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuji","family":"Sekiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuharu","family":"Miyazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Kusano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Asano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Kuro-o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,6,5]]},"reference":[{"issue":"37","key":"ref1","doi-asserted-by":"crossref","first-page":"26687","DOI":"10.1074\/jbc.M704165200","article-title":"Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21","volume":"282","author":"H Kurosu","year":"2007","journal-title":"J Biol Chem"},{"issue":"6","key":"ref2","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI23606","article-title":"FGF-21 as a novel metabolic regulator","volume":"115","author":"A Kharitonenkov","year":"2005","journal-title":"J Clin Invest"},{"issue":"6","key":"ref3","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.cmet.2007.05.002","article-title":"Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states","volume":"5","author":"MK Badman","year":"2007","journal-title":"Cell Metab"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1540267","DOI":"10.1155\/2016\/1540267","article-title":"Physiological and Pharmacological Roles of FGF21 in Cardiovascular Diseases","volume":"2016","author":"P Cheng","year":"2016","journal-title":"J Diabetes Res"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"19776","DOI":"10.1038\/srep19776","article-title":"Circulating Fibroblast Growth Factor 21 Is A Sensitive Biomarker for Severe Ischemia\/reperfusion Injury in Patients with Liver Transplantation","volume":"6","author":"D Ye","year":"2016","journal-title":"Sci Rep"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1038\/ncomms3019","article-title":"Fibroblast growth factor 21 protects against cardiac hypertrophy in mice","volume":"4","author":"A Planavila","year":"2013","journal-title":"Nat Commun"},{"issue":"18","key":"ref7","doi-asserted-by":"crossref","first-page":"7432","DOI":"10.1073\/pnas.0701600104","article-title":"BetaKlotho is required for metabolic activity of fibroblast growth factor 21","volume":"104","author":"Y Ogawa","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"ref8","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.2337\/db07-1476","article-title":"Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans","volume":"57","author":"X Zhang","year":"2008","journal-title":"Diabetes"},{"issue":"8","key":"ref9","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.2337\/dc09-0684","article-title":"Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance","volume":"32","author":"AO Chavez","year":"2009","journal-title":"Diabetes Care"},{"issue":"4","key":"ref10","doi-asserted-by":"crossref","first-page":"e18398","DOI":"10.1371\/journal.pone.0018398","article-title":"Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese","volume":"6","author":"Z Lin","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"ref11","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/j.1532-5415.2011.03879.x","article-title":"Serum fibroblast growth factor 21 is associated with renal function and chronic kidney disease in community-dwelling adults","volume":"60","author":"C Crasto","year":"2012","journal-title":"J Am Geriatr Soc"},{"issue":"11","key":"ref12","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1016\/j.metabol.2010.03.018","article-title":"Serum fibroblast growth factor-21 concentration is associated with residual renal function and insulin resistance in end-stage renal disease patients receiving long-term peritoneal dialysis","volume":"59","author":"SH Han","year":"2010","journal-title":"Metabolism"},{"issue":"3","key":"ref13","doi-asserted-by":"crossref","first-page":"e0151698","DOI":"10.1371\/journal.pone.0151698","article-title":"Fibroblast Growth Factor 21 (FGF-21) in Peritoneal Dialysis Patients: Natural History and Metabolic Implications","volume":"11","author":"E Gonzalez","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"ref14","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1210\/jc.2014-3465","article-title":"Circulating fibroblast growth factor 21 levels predict progressive kidney disease in subjects with type 2 diabetes and normoalbuminuria","volume":"100","author":"CH Lee","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"ref15","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/ki.2015.199","article-title":"Biomarkers of rapid chronic kidney disease progression in type 2 diabetes","volume":"88","author":"HC Looker","year":"2015","journal-title":"Kidney Int"},{"issue":"2","key":"ref16","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.diabres.2013.04.010","article-title":"Serum fibroblast growth factor 21 is predictive of combined cardiovascular morbidity and mortality in patients with type 2 diabetes at a relatively short-term follow-up","volume":"101","author":"M Lenart-Lipinska","year":"2013","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"ref17","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s00125-014-3458-7","article-title":"The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study","volume":"58","author":"KL Ong","year":"2015","journal-title":"Diabetologia"},{"issue":"12","key":"ref18","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1210\/jc.2016-2308","article-title":"Association Between Serum Fibroblast Growth Factor 21 and Mortality Among Patients With Coronary Artery Disease","volume":"101","author":"Q Li","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"ref19","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1093\/ndt\/gfq756","article-title":"Sleep-disordered breathing predicts cardiovascular events and mortality in hemodialysis patients","volume":"26","author":"T Masuda","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"406269","DOI":"10.1155\/2015\/406269","article-title":"Association between Serum Soluble Klotho Levels and Mortality in Chronic Hemodialysis Patients","volume":"2015","author":"N Otani-Takei","year":"2015","journal-title":"Int J Endocrinol"},{"issue":"6","key":"ref21","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1373\/clinchem.2011.163634","article-title":"Executive summary: guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus","volume":"57","author":"DB Sacks","year":"2011","journal-title":"Clin Chem"},{"issue":"3","key":"ref22","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1159\/000187980","article-title":"Determination of Kt\/V and protein catabolic rate using pre- and postdialysis blood urea nitrogen concentrations","volume":"67","author":"T Shinzato","year":"1994","journal-title":"Nephron"},{"issue":"6","key":"ref23","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/cen.12380","article-title":"Serum levels of fibroblast growth factor-21 are increased in chronic and acute renal dysfunction","volume":"80","author":"J Hindricks","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"ref24","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.2040-1124.2010.00074.x","article-title":"Report of the committee on the classification and diagnostic criteria of diabetes mellitus","volume":"1","author":"Y Seino","year":"2010","journal-title":"J Diabetes Investig"},{"issue":"1","key":"ref25","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1210\/jc.2015-3308","article-title":"Endurance Exercise Reduces Hepatic Fat Content and Serum Fibroblast Growth Factor 21 Levels in Elderly Men","volume":"101","author":"H Taniguchi","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"ref26","doi-asserted-by":"crossref","first-page":"e0173468","DOI":"10.1371\/journal.pone.0173468","article-title":"Development of a new risk model for predicting cardiovascular events among hemodialysis patients: Population-based hemodialysis patients from the Japan Dialysis Outcome and Practice Patterns Study (J-DOPPS)","volume":"12","author":"Y Matsubara","year":"2017","journal-title":"PLoS One"},{"issue":"5","key":"ref27","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/ki.2014.419","article-title":"Development and validation of a predictive mortality risk score from a European hemodialysis cohort","volume":"87","author":"J Floege","year":"2015","journal-title":"Kidney Int"},{"issue":"10","key":"ref28","doi-asserted-by":"crossref","first-page":"E1319","DOI":"10.1210\/jc.2015-2700","article-title":"FGF21 Response to Critical Illness: Effect of Blood Glucose Control and Relation With Cellular Stress and Survival","volume":"100","author":"SE Thiessen","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"ref29","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1530\/EC-13-0040","article-title":"Increased FGF21 plasma levels in humans with sepsis and SIRS","volume":"2","author":"K Gariani","year":"2013","journal-title":"Endocr Connect"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1471-230X-13-67","article-title":"Activation of Liver FGF21 in hepatocarcinogenesis and during hepatic stress","volume":"13","author":"C Yang","year":"2013","journal-title":"BMC Gastroenterol"},{"issue":"5","key":"ref31","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1053\/j.gastro.2009.07.064","article-title":"Fibroblast growth factor 21 reduces the severity of cerulein-induced pancreatitis in mice","volume":"137","author":"CL Johnson","year":"2009","journal-title":"Gastroenterology"},{"issue":"3","key":"ref32","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/hep.27060","article-title":"Fibroblast growth factor 21 protects against acetaminophen-induced hepatotoxicity by potentiating peroxisome proliferator-activated receptor coactivator protein-1alpha-mediated antioxidant capacity in mice","volume":"60","author":"D Ye","year":"2014","journal-title":"Hepatology"},{"issue":"4","key":"ref33","doi-asserted-by":"crossref","first-page":"245","DOI":"10.4093\/dmj.2014.38.4.245","article-title":"FGF21 as a Stress Hormone: The Roles of FGF21 in Stress Adaptation and the Treatment of Metabolic Diseases","volume":"38","author":"KH Kim","year":"2014","journal-title":"Diabetes Metab J"},{"issue":"12","key":"ref34","doi-asserted-by":"crossref","first-page":"H1446","DOI":"10.1152\/ajpheart.00362.2012","article-title":"Cardioprotective proteins upregulated in the liver in response to experimental myocardial ischemia","volume":"303","author":"SQ Liu","year":"2012","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1038\/srep02767","article-title":"Endocrine protection of ischemic myocardium by FGF21 from the liver and adipose tissue","volume":"3","author":"SQ Liu","year":"2013","journal-title":"Sci Rep"},{"issue":"2","key":"ref36","doi-asserted-by":"crossref","first-page":"e87102","DOI":"10.1371\/journal.pone.0087102","article-title":"Novel insights into the cardio-protective effects of FGF21 in lean and obese rat hearts","volume":"9","author":"V Patel","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"ref37","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2337\/dc08-1054","article-title":"Serum levels of the adipokine FGF21 depend on renal function","volume":"32","author":"S Stein","year":"2009","journal-title":"Diabetes Care"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.redox.2016.12.024","article-title":"Fibroblast growth factor 21 and its novel association with oxidative stress","volume":"11","author":"MA Gomez-Samano","year":"2017","journal-title":"Redox Biol"},{"issue":"7","key":"ref39","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1093\/ndt\/gfg074","article-title":"Oxidative stress in end-stage renal disease: an emerging threat to patient outcome","volume":"18","author":"F Locatelli","year":"2003","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"ref40","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.3181\/0704-MR-103","article-title":"Inflammation and oxidative stress in obstructive sleep apnea syndrome","volume":"232","author":"C Selmi","year":"2007","journal-title":"Exp Biol Med (Maywood)"},{"issue":"3","key":"ref41","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1530\/EJE-12-0357","article-title":"Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21","volume":"167","author":"P Iglesias","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"ref42","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cmet.2013.08.005","article-title":"The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes","volume":"18","author":"G Gaich","year":"2013","journal-title":"Cell Metab"},{"issue":"6","key":"ref43","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cmet.2007.05.003","article-title":"Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21","volume":"5","author":"T Inagaki","year":"2007","journal-title":"Cell Metab"},{"issue":"3","key":"ref44","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jdiacomp.2014.12.015","article-title":"Blood glucose fluctuations in hemodialysis patients with end stage diabetic nephropathy","volume":"29","author":"YP Jin","year":"2015","journal-title":"J Diabetes Complications"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0178971","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T09:17:41Z","timestamp":1540199861000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0178971"}},"subtitle":[],"editor":[{"given":"Tatsuo","family":"Shimosawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,6,5]]},"references-count":44,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,6,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0178971","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,5]]}}}